Login to Your Account

Medarex Sharing up to $225M from Antibody Deal with Merck

By Catherine Hollingsworth

Wednesday, April 22, 2009
A combination of monoclonal antibodies co-developed by Medarex Inc. and Massachusetts Biologic Laboratories has been licensed to drug giant Merck & Co. Inc. in a deal worth up to $225M. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription